San­thera gears up for EU launch of va­morolone in Duchenne af­ter pos­i­tive CHMP opin­ion

Swiss biotech San­thera has se­cured a pos­i­tive opin­ion for va­morolone from the EU’s CHMP for pa­tients with Duchenne mus­cu­lar dy­s­tro­phy (DMD), spark­ing plans for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER